Kura Oncology (NASDAQ:KURA) Raised to "Buy" at StockNews.com

StockNews.com upgraded shares of Kura Oncology (NASDAQ:KURA - Free Report) from a hold rating to a buy rating in a research note released on Friday.

Other analysts have also issued reports about the company. JMP Securities restated a "market outperform" rating and issued a $28.00 target price on shares of Kura Oncology in a research note on Thursday, February 6th. Cantor Fitzgerald upgraded Kura Oncology to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Kura Oncology in a research report on Thursday, February 27th. Jefferies Financial Group reduced their target price on Kura Oncology from $32.00 to $28.00 and set a "buy" rating for the company in a research report on Thursday, November 21st. Finally, BTIG Research cut Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $25.50.

Remove Ads

Kura Oncology Stock Performance

Kura Oncology stock traded down $0.17 during mid-day trading on Friday, reaching $7.53. 1,291,397 shares of the company's stock were exchanged, compared to its average volume of 1,591,525. The business's fifty day simple moving average is $8.00 and its 200 day simple moving average is $13.29. The firm has a market capitalization of $608.09 million, a PE ratio of -3.19 and a beta of 0.85. Kura Oncology has a one year low of $6.98 and a one year high of $24.17. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. On average, sell-side analysts expect that Kura Oncology will post -2.44 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares of the company's stock, valued at $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares of the company's stock, valued at $694,078.91. The trade was a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,729 shares of company stock valued at $92,307. Corporate insiders own 5.50% of the company's stock.

Hedge Funds Weigh In On Kura Oncology

Large investors have recently made changes to their positions in the business. Virtus ETF Advisers LLC lifted its position in shares of Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after acquiring an additional 3,061 shares in the last quarter. Point72 DIFC Ltd bought a new stake in shares of Kura Oncology in the third quarter worth about $146,000. Harbor Advisors LLC bought a new stake in shares of Kura Oncology in the fourth quarter worth about $87,000. E Fund Management Co. Ltd. bought a new stake in shares of Kura Oncology in the fourth quarter worth about $90,000. Finally, Erste Asset Management GmbH bought a new stake in shares of Kura Oncology in the third quarter worth about $215,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.